Pfizer Shares Slip Amidging Investor Interest in SCD Pipeline Uncertainty

Pfizer (ticker PFE) closed the trading session on October 2, 2026 at exactly $27.80, reflecting a decline of 1.24% for the day. This movement comes amid renewed investor focus on the uncertain outlook for the company’s sickle cell disease (SCD) development pipeline.

Leading concerns is the fate of Oxbryta (voxelotor), which Pfizer voluntarily withdrew from the market amid safety concerns. The company recently confirmed that discussions with the U.S. Food and Drug Administration have concluded there is no viable path to reintroduce the drug in the U.S.

At the same time, Pfizer’s late-stage candidate inclacumab, a P-selectin inhibitor acquired via its Global Blood Therapeutics deal, has shown disappointing efficacy. The Phase 3 THRIVE‑131 study failed to meet its primary endpoint, showing no significant reduction in vaso-occlusive crises compared to placebo, despite being generally well tolerated . A second Phase 3 trial was previously terminated due to slow patient enrollment .

With both leading SCD programs—Oxbryta and inclacumab—now faltering or unlikely to return, attention turns to osivelotor, an HbS polymerization inhibitor currently in Phase 3 development. The FDA had imposed a partial clinical hold on osivelotor, but subsequently lifted restrictions on enrollment outside sub‑Saharan Africa . Pfizer has indicated it will channel future SCD research efforts toward osivelotor moving forward .

The convergence of these developments has raised investor caution, as the company’s roadmap for delivering value in the SCD space remains unclear. With two key SCD assets now jeopardized, the future of Pfizer’s $5.4 billion Global Blood Therapeutics acquisition has come into sharper question.

What to watch next: Whether osivelotor can advance safely and demonstrate clinical benefit in its Phase 3 program—or if new SCD assets emerge from Pfizer’s pipeline—will be critical to restoring investor confidence in this therapeutic area.